DGCRFOTCHealthcare · Medical - Specialties

Diagnocure, Inc.

$0.00+0.00%(+$0.00)

TickerSpark Score

54/100

Mixed

100

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGCRF research report →

52-Week Range100% of range

Low $0.00

Current $0.00

High $0.00

Companywww.diagnocure.com

Diagnocure, Inc. , a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer.

CEO: Yves Fradet F.R.C.S.,
IPO: 2009
Employees: 3
HQ: Quebec, QC, CA

Price Chart

+900.00% · this period

Valuation

Market Cap: $21.52K
P/E: -0.00
P/S: 0.06
P/B: 0.00
EV/EBITDA: 0.19
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -294.02%
Net Margin: -698.56%
ROE: -110.73%
ROIC: -102.04%

Growth & Income

Revenue: $515.37K · -6.83%
Net Income: $-3,600,168 · -77.16%
EPS: $-0.11 · -96.08%
Op Income: $-1,515,318
FCF YoY: 38.07%

Performance & Tape

52W High: $0.00
52W Low: $0.00
50D MA: $0.00
200D MA: $0.00
Beta: -15.95
Avg Volume: 2.57K

Get TickerSpark's AI analysis on DGCRF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime